Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
ARVINAS, INC. (ARVN) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/08/2023 8-K Investor presentation
Docs: "EXHIBIT 99.1 Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line",
"June 8, 2023 ARV-766: Phase 1 and"
01/09/2023 8-K Investor presentation
Docs: "J.P. Morgan Healthcare Conference January 11, 2023"
12/08/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/21/2022 8-K Quarterly results
02/17/2022 8-K Investor presentation
Docs: "Arvinas PROTAC ® Protein Degrader Bavdegalutamide Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer",
"Company Presentation"
12/10/2021 8-K Quarterly results
12/14/2020 8-K Investor presentation
Docs: "Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC ® Protein Degraders ARV-471 and ARV-110",
"Company Presentation"
05/29/2020 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 29, 2020 Arvinas, Inc. Delaware 001-38672 47-2566120 5 Science Park 395 Winchester Ave. New Haven, Connecticut 06511 Registrant's telephone number, including area code: 535-1456 Not applicable",
"Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC ® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer",
"Company Presentation"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy